Showing 12,861 - 12,880 results of 21,342 for search '(( significant decrease decrease ) OR ( significant ((teer decrease) OR (nn decrease)) ))', query time: 0.55s Refine Results
  1. 12861

    Experience-dependent and temporally restricted serotonin signaling and synaptic glomeruli pruning. by Vanessa Kay Miller (19775496)

    Published 2024
    “…Two-way ANOVA with Tukey’s multiple comparison shows a highly significant decrease in the Or42a OSN innervation (<i>n</i> = 28/condition, <i>p</i> = 7.45 × 10<sup>−11</sup>) and increase in serotonin (<i>n</i> = 28/condition, <i>p</i> = 4.10 × 10<sup>−14</sup>). …”
  2. 12862

    Data Sheet 1_Clinical predictors and concomitant antiseizure medications effects on seizure control in relation to plasma cenobamate concentration: a multicenter retrospective stud... by Francesca Felicia Operto (12509263)

    Published 2025
    “…Among responders, 53.8% (14/26) achieved response on ≤100 mg/day, with CNBp of 0.5–17.6 μg/mL (median ∼5–6 μg/mL). There was no significant relationship between age and gender, although there was a statistically significant correlation between CNBp and BMI (p = 0.038; R2 = 0.157). …”
  3. 12863

    Data_Sheet_1_The efficacy and safety of isotonic and hypotonic fluids in intravenous maintenance fluid therapy in term newborns: national multicenter observational “neofluid” study... by Hasan Ozkan (6808268)

    Published 2024
    “…The hypotonic fluid group had a higher incidence of hyponatremia and a clinically meaningful sodium decrease compared to the isotonic fluid group [7.9% vs. 1.2% (OR:6.5, p:0.03)] and [12.2% vs.4.2% (OR:2.9, p = 0.03)].…”
  4. 12864

    DataSheet3_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

    Published 2024
    “…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”
  5. 12865

    5OMV Inhibits HMGB1-Induced Tube Formation in HUVECs. by Wenyue Hou (10203722)

    Published 2025
    “…Mean values showing significant differences between the control group and the HMGB1-treated group are indicated by *(<i>P</i> < 0.05) or ** (<i>P</i> < 0.01). …”
  6. 12866

    Key factors affecting enterprise competitiveness and business efficiency: a case study of tourism enterprises in Vietnam by Phan Thanh Tam (19969603)

    Published 2024
    “…<p>Vietnam’s tourism business has been dramatically affected by the Covid‑19 outbreak, leading to a considerable decrease in the number of tourists visiting the country. …”
  7. 12867

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  8. 12868

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  9. 12869

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  10. 12870

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  11. 12871

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  12. 12872

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  13. 12873

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  14. 12874

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  15. 12875

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  16. 12876

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  17. 12877

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  18. 12878

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  19. 12879

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  20. 12880